Viking Therapeutics Advances VK2735 Trials with Q4 2024 Financial Update
February 7, 2025 - 02:25
Viking Therapeutics has provided an update on its financial performance for the fourth quarter of 2024 while highlighting the progress of its oral VK2735 in Phase 2 clinical trials. The company reported significant advancements in its research and development efforts, particularly focusing on VK2735, a novel therapeutic candidate aimed at addressing metabolic disorders.
The Phase 2 trials are crucial for determining the efficacy and safety of VK2735, with results anticipated in the second half of 2025. This timeline positions Viking Therapeutics to potentially make substantial contributions to the treatment landscape for conditions such as obesity and type 2 diabetes. The company is optimistic about the ongoing trials and remains committed to delivering innovative solutions for patients.
In addition to the clinical advancements, Viking's financial results reflect a strategic approach to funding its research initiatives. The company continues to explore opportunities for growth and collaboration in the biotechnology sector, ensuring that it remains at the forefront of medical innovation.
MORE NEWS
May 22, 2026 - 09:13
Q1 Earnings Highs And Lows: 1st Source (NASDAQ:SRCE) Vs The Rest Of The Regional Banks StocksThe first quarter earnings season for regional banks has wrapped up, revealing a clear divide between winners and laggards. While some institutions managed to navigate a tricky environment of...
May 21, 2026 - 22:00
White House Executive Order Signals Major Shift in Federal Policy for Fintechs and Payment SystemsPresident Donald Trump issued a new executive order on Thursday aimed at overhauling how the federal government approaches financial technology and payment systems, marking a major policy shift for...
May 21, 2026 - 01:01
Fed meeting minutes: Officials look to hold rates for longer, consider hikes if inflation remains highFederal Reserve officials signaled they are prepared to keep interest rates higher for longer than previously expected, and some even discussed the possibility of raising rates again if inflation...
May 20, 2026 - 08:54
Assessing Voya Financial’s Valuation After Recent Share Price MomentumVoya Financial (VOYA) has been drawing attention after recent trading, with the stock last closing at US$80. With a market cap of about US$7.4 billion, investors are weighing how its mixed return...